2 suspended. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Suspended 2 |
| Phase 1 | 1 | Suspended 1 |
Follow Rituxan: new trials by email Literature Review of Rituxan trials Research Report on Rituxan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab - Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Suspended | Northwestern University | 30 | 2018-11-20 | 2022-08-15 |
Burkitt Lymphoma (1) · Lymphoma, B-Cell (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Northwestern University (1) · University of Washington (1)
United States (2)
Reem Karmali, MD (1) · Ryan D. Cassaday, MD (1)
P30CA060553 (1)